Last reviewed · How we verify
Baraclude Tab. 0.5mg
At a glance
| Generic name | Baraclude Tab. 0.5mg |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation (NA)
- Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B (PHASE4)
- Finite Versus Continuous Nucleos(t)Ide Analogues for Chronic Hepatitis B (NA)
- The Relationship Between Long-term Oral Anti Hepatitis B Nucleoside Analogs and Hepatic Steatosis
- An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy (PHASE2)
- Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis (PHASE4)
- Optimized Treatment and Regression of HBV-induced Early Cirrhosis (PHASE4)
- Optimized Treatment and Regression of HBV-induced Liver Fibrosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baraclude Tab. 0.5mg CI brief — competitive landscape report
- Baraclude Tab. 0.5mg updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI